HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Markus D Siegelin Selected Research

navitoclax

8/2020Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma.
10/2019Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.
10/2018Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
1/2018Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
5/2017BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
9/2016A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
6/2016Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
3/2016Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
11/2015TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
6/2015Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Markus D Siegelin Research Topics

Disease

36Neoplasms (Cancer)
06/2021 - 11/2008
34Glioblastoma (Glioblastoma Multiforme)
11/2021 - 06/2010
16Glioma (Gliomas)
12/2019 - 11/2008
3Melanoma (Melanoma, Malignant)
10/2019 - 02/2009
2Neoplasm Metastasis (Metastasis)
05/2021 - 02/2009
2Carcinogenesis
12/2019 - 06/2013
2Brain Neoplasms (Brain Tumor)
09/2019 - 03/2016
1Starvation
01/2021
1Medulloblastoma
01/2021
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
11/2020
1Cardiomyopathies (Cardiomyopathy)
11/2020
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2019
1Cholangiocarcinoma
12/2019
1Carcinoma (Carcinomatosis)
10/2019
1Infections
12/2017
1Triple Negative Breast Neoplasms
01/2017
1Leukemia
11/2015
1Adenocarcinoma of Lung
02/2014
1Adenocarcinoma
02/2014
1Neuroblastoma
01/2014
1Mitochondrial Diseases (Mitochondrial Disease)
10/2010
1Prostatic Neoplasms (Prostate Cancer)
10/2010

Drug/Important Bio-Agent (IBA)

14Proteins (Proteins, Gene)FDA Link
01/2021 - 02/2009
11navitoclaxIBA
08/2020 - 07/2014
9Pharmaceutical PreparationsIBA
11/2021 - 11/2008
6Transcription Factors (Transcription Factor)IBA
05/2021 - 04/2011
5Drug CombinationsIBA
11/2018 - 11/2015
4Small Interfering RNA (siRNA)IBA
01/2020 - 09/2009
4LigandsIBA
09/2016 - 11/2008
3Peptides (Polypeptides)IBA
05/2021 - 03/2016
3TIC10 compoundIBA
01/2021 - 11/2015
3Temozolomide (Temodar)FDA LinkGeneric
01/2021 - 09/2019
3SurvivinIBA
01/2019 - 11/2008
3Deubiquitinating EnzymesIBA
09/2016 - 11/2015
3Indicators and Reagents (Reagents)IBA
09/2016 - 03/2016
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2009 - 11/2008
2Glucose (Dextrose)FDA LinkGeneric
06/2021 - 01/2021
2CarbonIBA
06/2021 - 10/2019
2PanobinostatIBA
10/2020 - 01/2018
2Histone Deacetylases (Histone Deacetylase)IBA
10/2020 - 01/2018
2CrizotinibIBA
01/2020 - 01/2018
2Phosphotransferases (Kinase)IBA
01/2020 - 03/2015
2Liver X ReceptorsIBA
10/2019 - 06/2019
22- (2- chloro- 4- fluorobenzyl)- 3- (4- fluorophenyl)- 7- (trifluoromethyl)- 2H- indazoleIBA
10/2019 - 06/2019
2CholesterolIBA
10/2019 - 06/2019
2Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
06/2019 - 11/2010
2OTX015IBA
01/2018 - 05/2017
2Adenosine Triphosphate (ATP)IBA
01/2018 - 10/2017
2Sorafenib (BAY 43-9006)FDA Link
01/2018 - 07/2010
2obatoclaxIBA
05/2017 - 06/2015
2Death Domain ReceptorsIBA
04/2011 - 04/2009
2FlavonoidsIBA
04/2009 - 11/2008
1Lactic Acid (Lactate)FDA LinkGeneric
06/2021
1Aurora Kinase AIBA
01/2021
1Deoxyglucose (2 Deoxy D glucose)IBA
01/2021
1GTP Phosphohydrolases (GTPases)IBA
01/2021
1Ribosomal Proteins (Ribosomal Protein)IBA
11/2020
1romidepsin (FK228)FDA Link
10/2020
1Fatty Acids (Saturated Fatty Acids)IBA
01/2020
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2020
1Histone Deacetylase InhibitorsIBA
01/2020
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
12/2019
1BAY 1436032IBA
12/2019
1alpha-hydroxyglutarateIBA
12/2019
1EnzymesIBA
12/2019
1GW 3965IBA
10/2019
1Alkylating AgentsIBA
09/2019
1Biomarkers (Surrogate Marker)IBA
11/2018
1ONC212IBA
11/2018
1ONC206IBA
11/2018
1Initiator CaspasesIBA
10/2018
1selinexorIBA
10/2018
1SulfonesIBA
12/2017
1DapsoneFDA Link
12/2017
1Anti-Bacterial Agents (Antibiotics)IBA
12/2017
1Biological ProductsIBA
12/2017
1Antineoplastic Agents (Antineoplastics)IBA
09/2016
1Amino AcidsFDA Link
06/2016
1Asparaginase (Elspar)FDA Link
06/2016
1degrasynIBA
03/2016
1BH 3IBA
06/2015
12- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA
07/2014
1ErbB Receptors (EGF Receptor)IBA
02/2014
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2014
1N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA
01/2014
1Heat-Shock Proteins (Heat-Shock Protein)IBA
06/2013
1CCAAT-Enhancer-Binding ProteinsIBA
04/2011
1Mitochondrial Permeability Transition PoreIBA
11/2010
1Chaperonin 60IBA
11/2010
1tanespimycin (17AAG)IBA
10/2010
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
10/2010
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
10/2010
1CaspasesIBA
10/2010
1Hormones (Hormone)IBA
10/2010
1Cytochromes c (Cytochrome c)IBA
10/2010
1Molecular Chaperones (Chaperone, Molecular)IBA
06/2010

Therapy/Procedure

32Therapeutics
05/2021 - 11/2008
2Radiotherapy
09/2019 - 11/2018
1Stem Cell Transplantation
01/2021
1Ligation
04/2011